Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Cocktail Blood Biomarkers: Prediction of Clinical Outcomes in Patients with Acute Ischemic Stroke

Zeng L.a, b · Liu J.a · Wang Y.b, c · Wang L.a · Weng S.a · Chen S.a · Yang G.-Y.a–c

Author affiliations

aDepartment of Neurology, Ruijin Hospital, bNeuroscience and Neuroengineering Center, Med-X Research Institute, and cSchool of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China

Related Articles for ""

Eur Neurol 2013;69:68–75

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 14, 2012
Accepted: August 16, 2012
Published online: November 14, 2012
Issue release date: February 2013

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Abstract

Background: Timely prediction of stroke outcomes is important for proper personalized treatment. In the present study, we aimed to develop cocktail blood biomarkers to increase prediction efficiency using a combination of hemostasis, inflammatory and repair-related biomarkers. Methods: 105 patients suffering from acute ischemic stroke were divided into good outcome group and poor outcome group by modified Rankin Scale (mRS). Cytokines including CD40L, IFN-γ, IL-1α, IL-1β, IL-6, IL-8, IL-17 and TNF-α, as well as hemostasis markers fibrinogen, fibrin degradation products (FDP), D-dimer, tissue plasminogen activator, and plasminogen activation inhibitor-1 in plasma were examined by ELISA. Repair-related biomarker microRNA-210 (miR-210) was measured by real-time PCR. The prediction efficiency was explored by receiver operator characteristic analysis. Results: We demonstrated that FDP, IL-6 and miR-210 levels were closely associated with mRS in stroke patients. The prediction sensitivity of FDP, IL-6 and miR-210 for stroke outcome was 72.0, 86.7 and 82.5%, respectively. Using a combination of biomarkers including FDP, IL-6 and miR-210, the prognostic sensitivity of ischemic stroke increased to 95.2%. Conclusion: The combination of FDP, IL-6 and miR-210 has a high sensitivity for predicting stroke recovery, it serves as a potential cocktail blood biomarker. It provides a novel approach for stroke prognosis.

© 2012 S. Karger AG, Basel


References

  1. Whiteley W, Chong WL, Sengupta A, Sandercock P: Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009;40:e380–e389.
  2. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH: Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 2009;73:393–399.
  3. Saenger AK, Christenson RH: Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 2010;56:21–33.
  4. Piskunov A: Neuroinflammation biomarkers. Neurochemical Journal 2010;4:55–63.
    External Resources
  5. Manolescu BN, Berteanu M, Dumitru L, et al: Dynamics of inflammatory markers in post-acute stroke patients undergoing rehabilitation. Inflammation 2011;34:551–558.
  6. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC: Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009;40:77–85.
    External Resources
  7. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J: Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry 2011;82:986–992.
  8. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al: Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol 2009;215:84–89.
  9. Whiteley W, Wardlaw J, Dennis M, et al: The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012;43:86–91.
  10. Castellanos M, Serena J: Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007;24(suppl 1):7–15.
  11. Suzuki Y, Urano T: Novel situations of endothelial injury in stroke – mechanisms of stroke and strategy of drug development: novel mechanism of the expression and amplification of cell surface-associated fibrinolytic activity demonstrated by real-time imaging analysis. J Pharmacol Sci 2011;116:19–24.
  12. Doyle KP, Simon RP, Stenzel-Poore MP: Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310–318.
  13. Ekdahl C, Kokaia Z, Lindvall O: Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009;158:1021–1029.
  14. Zeng L, Liu J, Wang Y, et al: MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia. Front Biosci (Elite Ed) 2011;3:1265–1272.
  15. Sotgiu S, Zanda B, Marchetti B, et al: Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006;13:505–513.
  16. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G: Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 2008;14:3574–3589.
  17. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V: Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008;41:1330–1334.
  18. Foca A, Berlinghieri MC, Barreca GS, et al: Kinetics of IL-8, MIP-1 alpha, TNF alpha, IL-1 beta, IL-1ra and IL-10 in human whole blood samples triggered by smooth and rough LPS. New Microbiol 1998;21:123–130.
  19. Eggesbo JB, Hjermann I, Hostmark AT, Kierulf P: LPS induced release of IL-1 beta, IL-6, IL-8 and TNF-alpha in EDTA or heparin anticoagulated whole blood from persons with high or low levels of serum HDL. Cytokine 1996;8:152–160.
  20. Davi G, Tuttolomondo A, Santilli F, et al: CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb 2009;16:707–713.
  21. Jin R, Yang G, Li G: Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010;87:779–789.
  22. Shichita T, Sugiyama Y, Ooboshi H, et al: Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 2009;15:946–950.
  23. Wang DD, Zhao YF, Wang GY, et al: IL-17 potentiates neuronal injury induced by oxygen-glucose deprivation and affects neuronal IL-17 receptor expression. J Neuroimmunol 2009;212:17–25.
  24. Kebir H, Kreymborg K, Ifergan I, et al: Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173–1175.
  25. Kishimoto T: IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347–352.
  26. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M: IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012;122:143–159.
  27. Waje-Andreassen U, Krakenes J, Ulvestad E, et al: IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005;111:360–365.
  28. Cojocaru IM, Cojocaru M, Tanasescu R, Iliescu I, Dumitrescu L, Silosi I: Expression of IL-6 activity in patients with acute ischemic stroke. Rom J Intern Med 2009;47:393–396.
  29. Ferrarese C, Mascarucci P, Zoia C, et al: Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999;19:1004–1009.
  30. Tarkowski E, Rosengren L, Blomstrand C, et al: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995;26:1393–1398.
  31. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al: Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol 2009;215:84–89.
  32. Rothwell PM, Howard SC, Power DA, et al: Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004;35:2300–2305.
  33. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ: D-dimer predicts early clinical progression in ischemic stroke: confirmation using routine clinical assays. Stroke 2006;37:1113–1115.
  34. Lu FM, Lin SY: Effects of FDP and Danshen on renal cortical Na-K-ATPase activity in rats after treatment with renal ischemia and gentamicin. Chin Med J (Engl) 1989;102:516–523.
  35. Malusardi R, Oddone A, Orlandi M, Manzi G: [Fructose-1,6-diphosphate (FDP) in transitory myocardial ischemia induced by atrial pacing]. Minerva Cardioangiol 1988;36:439–444.
  36. Denti L, Annoni V, Cattadori E, et al: Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004;117:312–317.
  37. Rink C, Khanna S: MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics 2011;43:521–528.
  38. Liu DZ, Tian Y, Ander BP, et al: Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab 2010;30:92–101.
  39. Chan SY, Loscalzo J: MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010;9:1072–1083.
  40. Hu S, Huang M, Li Z, et al: MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010;122:S124–S131.
  41. Whiteley W, Wardlaw J, Dennis M, et al: Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovasc Dis 2011;32:141–147.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 14, 2012
Accepted: August 16, 2012
Published online: November 14, 2012
Issue release date: February 2013

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.